Treatments for choroidal and retinal neovascularization: A focus on oligonucleotide therapy and delivery for the regulation of gene function

Clinical and Experimental Ophthalmology

Volumn 33, Issue 1, 2005, Pages 81-89

  Marano, Robert J ^a   Rakoczy, P Elizabeth ^b  

^a LIONS EYE INSTITUTE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Gene therapy; Neovascularization; Oligonucleotides; Vascular endothelial growth factor (VEGF)

Indexed keywords

ALPHA TOCOPHEROL; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; APTAMER; ASCORBIC ACID; BETA CAROTENE; DENDRIMER; DS 085; ENDONUCLEASE; FOMIVIRSEN; IMMUNOGLOBULIN F(AB) FRAGMENT; LIPOPLEX; LIPOSOME; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGONUCLEOTIDE; PARVOVIRUS VECTOR; PEGAPTANIB; PHOTOSENSITIZING AGENT; PIGMENT EPITHELIUM DERIVED FACTOR; POLYGLACTIN; POLYNUCLEOTIDE; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ZINC;

ANGIOGENESIS; BLINDNESS; CELL TYPE; CELLULAR DISTRIBUTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME ACTIVITY; GENE CONTROL; GENE DELIVERY SYSTEM; GENE LOCATION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; IMMUNOPATHOLOGY; LASER COAGULATION; LONGEVITY; METABOLIC INHIBITION; NONHUMAN; PENETRANCE; RETINA NEOVASCULARIZATION; RETINITIS; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; VISUAL IMPAIRMENT; WESTERN HEMISPHERE;

CHOROIDAL NEOVASCULARIZATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; OLIGONUCLEOTIDES; RETINAL NEOVASCULARIZATION;

EID: 14744296810     PISSN: 14426404     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2005.00952.x     Document Type: Review

References (102)

1. Bainbridge JW, Mistry A, De Alwis M et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 2002; 9: 320-6.
2. Bressler NM. Evaluating new retinal imaging techniques. Arch Ophthalmol 1998; 116: 521-2.
3. Ferris FL, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984; 28 (Suppl.): 452-61.
4. Adamis AP, Miller JW, Bernal MT et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118 445-50.
5. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331 1480-7.
6. Malecaze F, Clamens S, Simorre-Pinatel V et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994; 112: 1476-82.
7. Boulton M, Foreman D, Williams G, McLeod D. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82: 561-8.
8. Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol 1998; 152: 1453-62.
9. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996; 114: 971-7.
10. Miller JW, Adamis AP, Shima DT et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-84.
11. Segawa Y, Shirao Y, Yamagishi S et al. Upregulation of retinal vascular endothelial growth factor mRNAs in spontaneously diabetic rats without ophthalmoscopic retinopathy: a possible participation of advanced glycation end products in the development of the early phase of diabetic retinopathy. Ophthalmic Res 1998; 30 333-9.
12. Okamoto N, Tobe T, Hackett SF et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997; 151: 281-91.
13. Baffi J, Byrnes G, Chan CC, Csaky KG. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 2000; 41: 3582-9.
14. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157: 135-44.
15. Ohno-Matsui K, Morita I, Tombran-Tink J et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 2001; 189: 323-33.
16. Dawson DW, Volpert OV, Gillis P et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-8.
17. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551-78.
18. Arnarsson A, Stefansson E. Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 2000; 41: 877-9.
19. Wilson AS, Hobbs BG, Speed TP, Rakoczy PE. The microarray: potential applications for ophthalmic research. Mol Vis 2002; 8 259-70.
20. Blumenkranz MS, Woodburn KW, Qing F, Verdooner S, Kessel D, Miller R. Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy. Am J Ophthalmol 2000; 129: 353-62.
21. Fine SL. Photodynamic therapy with verteporfin is effective for selected patients with neovascular age-related macular degeneration. Arch Ophthalmol 1999; 117: 1400-2.
22. Husain D, Kramer M, Kenny AG et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 1999; 40: 2322-31.
23. Pogue BW, Redmond RW, Trivedi N, Hasan T. Photophysical properties of tin ethyl etiopurpurin I (SnET2) and tin octaethylbenzochlorin (SnOEBC) in solution and bound to albumin. Photochem Photobiol 1998; 68: 809-15.
24. Jones MK, Wang H, Peskar BM et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-23.
25. Sawaoka H, Tsuji S, Tsujii M et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79: 1469-77.
26. Adamis AP, Shima DT, Tolentino MJ et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66-71.
27. Krzystolik MG, Afshari MA, Adamis AP et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120: 338-46.
28. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-61.
29. Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001; 98: 2593-7.
30. Auricchio A, Behling KC, Maguire AM et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002; 6: 490-4.
31. Lai CM, Brankov M, Zaknich T et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001; 12: 1299-310.
32. Lai CM, Spilsbury K, Brankov M, Zaknich T, Rakoczy PE. Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. Exp Eye Res 2002; 75: 625-34.
33. Mori K, Ando A, Gehlbach P et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001; 159 313-20.
34. Mori K, Gehlbach P, Yamamoto S et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43: 1994-2000.
35. Baum C, von Kalle C, Staal FJ et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004; 9: 5-13.
36. Newsome DA, Swartz M, Leone NC, Elston RC, Miller E. Oral zinc in macular degeneration. Arch Ophthalmol 1988; 106: 192-8.
37. Stur M, Tittl M, Reitner A, Meisinger V. Oral zinc and the second eye in age-related macular degeneration. Invest Ophthalmol Vis Sci 1996; 37: 1225-35.
38. Cho E, Stampfer MJ, Seddon JM et al. Prospective study of zinc intake and the risk of age-related macular degeneration. Ann Epidemiol 2001; 11: 328-36.
39. Gordon JE, Schooff M. Can high-dose supplementation with vitamins C and E, beta carotene, and zinc slow the progression of macular degeneration? J Fam Pract 2002; 51: 105.
40. Hopley C, Salkeld G, Wang JJ, Mitchell P. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol 2004; 88: 450-4.
41. Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 1977; 74: 4370-4.
42. Pirollo KF, Rait A, Steer LS, Chang EH. Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 2003; 99: 55-77.
43. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 1992; 32: 329-76.
44. Matveeva OV, Mathews DH, Tsodikov AD et al. Thermodynamic criteria for high hit rate antisense oligonucleotide design. Nucleic Acids Res 2003; 31: 4989-94.
45. Zain R, Sun JS. Do natural DNA triple-helical structures occur and function in vivo? Cell Mol Life Sci 2003; 60: 862-70.
46. Baran N, Lapidot A, Manor H. Formation of DNA triplexes accounts for arrests of DNA synthesis at d(TC)n and d(GA)n tracts. Proc Natl Acad Sci USA 1991; 88: 507-11.
47. Hacia JG, Dervan PB, Wold BJ. Inhibition of Klenow fragment DNA polymerase on double-helical templates by oligonucleotide-directed triple-helix formation. Biochemistry 1994; 33: 6192-200.
48. Rando RF, DePaolis L, Durland RH, Jayaraman K, Kessler DJ, Hogan ME. Inhibition of T7 and T3 RNA polymerase directed transcription elongation in vitro. Nucleic Acids Res 1994; 22: 678-85.
49. Samadashwily GM, Mirkin SM. Trapping DNA polymerases using triplex-forming oligodeoxyribonucleotides. Gene 1994; 149: 127-36.
50. Young SL, Krawczyk SH, Matteucci MD, Toole JJ. Triple helix formation inhibits transcription elongation in vitro. Proc Natl Acad Sci USA 1991; 88: 10023-6.
51. Krasilnikov AS, Panyutin IG, Samadashwily GM, Cox R, Lazurkin YS, Mirkin SM. Mechanisms of triplex-caused polymerization arrest. Nucleic Acids Res 1997; 25: 1339-46.
52. Giovannangeli C, Rougee M, Garestier T, Thuong NT, Helene C. Triple-helix formation by oligonucleotides containing the three bases thymine, cytosine, and guanine. Proc Natl Acad Sci USA 1992; 89 8631-5.
53. Cutroneo KR, Chiu JF. Sense oligonucleotide competition for gene promoter binding and activation. Int J Biochem Cell Biol 2003; 35: 32-8.
54. Park YG, Nesterova M, Agrawal S, Cho-Chung YS. Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide: gene-specific inhibition of tumor growth. J Biol Chem 1999; 274: 1573-80.
55. Clusel C, Meguenni S, Elias I, Vasseur M, Blumenfeld M. Inhibition of HSV-1 proliferation by decoy phosphodiester oligonucleotides containing ICP4 recognition sequences. Gene Expr 1995; 4: 301-9.
56. Morishita R, Gibbons GH, Horiuchi M et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-9.
57. Tomita N, Morishita R, Higaki J, Ogihara T. A novel strategy for gene therapy and gene regulation analysis using transcription factor decoy oligonucleotides. Exp Nephrol 1997; 5: 429-34.
58. Tomita N, Tomita T, Yuyama K et al. Development of novel decoy oligonucleotides: advantages of circular dumb-bell decoy. Curr Opin Mol Ther 2003; 5: 107-12.
59. Patel DJ, Suri AK. Structure, recognition and discrimination in RNA aptamer complexes with cofactors, amino acids, drugs and aminoglycoside antibiotics. J Biotechnol 2000; 74: 39-60.
60. Patel DJ, Suri AK, Jiang F et al. Structure, recognition and adaptive binding in RNA aptamer complexes. J Mol Biol 1997; 272: 645-64.
61. Gold L, Polisky B, Uhlenbeck O, Yarus M. Diversity of oligonucleotide functions. Annu Rev Biochem 1995; 64: 763-97.
62. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 818-22.
63. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249: 505-10.
64. Arenz C, Schepers U. RNA interference: from an ancient mechanism to a state of the art therapeutic application? Naturwissenschaften 2003; 90: 345-59.
65. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978; 75: 285-8.
66. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978; 75: 280-4.
67. Alama A, Barbieri F, Cagnoli M, Schettini G. Antisense oligonucleotides as therapeutic agents. Pharmacol Res 1997; 36 171-8.
68. Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. N Engl J Med 1996; 334: 316-18.
69. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer: the time of truth. Lancet Oncol 2002; 3: 672-83.
70. Azad RF, Driver VB, Tanaka K, Crooke RM, Anderson KP. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993; 37: 1945-54.
71. Group TVS. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133: 467-74.
72. Group TVS. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol 2002; 133: 475-83.
73. Group TVS. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133: 484-98.
74. Garrett KL, Shen WY, Rakoczy PE. In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye. J Gene Med 2001; 3: 373-83.
75. Wimmer N, Marano RJ, Kearns PS, Rakoczy PE, Toth I. Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides. Bioorg Med Chem Lett 2002; 12 2635-7.
76. Ruckman J, Green LS, Beeson J et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998; 273: 20556-67.
77. Bell C, Lynam E, Landfair DJ, Janjic N, Wiles ME. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 1999; 35: 533-42.
78. Tolentino MJ, Brucker AJ, Fosnot J et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004; 24: 132-8.
79. Savi P, Pflieger AM, Herault JP et al. Comparative effects of two synthetic oligosaccharides on platelet activation induced by plasma from HIT patients. J Thromb Haemost 2003; 1: 2008-13.
80. Urban E, Noe CR. Structural modifications of antisense oligonucleotides. Farmaco 2003; 58: 243-58.
81. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science 1993; 261: 1004-12.
82. Armitage BA. The impact of nucleic acid secondary structure on PNA hybridization. Drug Discov Today 2003; 8: 222-8.
83. Rakoczy PE, Lai MC, Watson M, Seydel U, Constable I. Targeted delivery of an antisense oligonucleotide in the retina: uptake, distribution, stability, and effect. Antisense Nucleic Acid Drug Dev 1996; 6: 207-13.
84. Shen WY, Rakoczy PE. Uptake dynamics and retinal tolerance of phosphorothioate oligonucleotide and its direct delivery into the site of choroidal neovascularization through subretinal administration in the rat. Antisense Nucleic Acid Drug Dev 2001; 11: 257-64.
85. Brignole C, Pagnan G, Marimpietri D et al. Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett 2003; 197: 231-5.
86. Chirila TV, Rakoczy PE, Garrett KL, Lou X, Constable IJ. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 2002; 23: 321-42.
87. Garcia-Chaumont C, Seksek O, Grzybowska J, Borowski E, Bolard J. Delivery systems for antisense oligonucleotides. Pharmacol Ther 2000; 87: 255-77.
88. Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001; 6: 303-15.
89. Lebedeva I, Benimetskaya L, Stein CA, Vilenchik M. Cellular delivery of antisense oligonucleotides. Eur J Pharm Biopharm 2000; 50: 101-19.
90. Lysik MA, Wu-Pong S. Innovations in oligonucleotide drug delivery. J Pharm Sci 2003; 92: 1559-73.
91. Miller KJ, Das SKU. Antisense oligonucleotides: strategies for delivery. Pharm Sci Technol Today 1998; 1: 377-86.
92. Takakura Y, Nishikawa M, Yamashita F, Hashida M. Development of gene drug delivery systems based on pharmacokinetic studies. Eur J Pharm Sci 2001; 13: 71-6.
93. Gait MJ. Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell Mol Life Sci 2003; 60 844-53.
94. Biessen EA, Vietsch H, Rump ET et al. Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem J 1999; 340: 783-92.
95. Willis M, Forssen E. Ligand-targeted liposomes. Adv Drug Deliv Rev 1998; 29: 249-71.
96. Haviv YS, Curiel DT. Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev 2001; 53: 135-54.
97. Sato N, Kobayashi H, Saga T et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res 2001; 7 3606-12.
98. Krotz F, de Wit C, Sohn HY et al. Magnetofection: a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther 2003; 7: 700-10.
99. Scherer F, Anton M, Schillinger U et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002; 9: 102-9.
100. De Rosa G, Bochot A, Quaglia F, Besnard M, Fattal E. A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes. Int J Pharm 2003; 254: 89-93.
101. De Rosa G, Quaglia F, La Rotonda M, Besnard M, Fattal E. Biodegradable microparticles for the controlled delivery of oligonucleotides. Int J Pharm 2002; 242: 225-8.
102. Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP. Controlled delivery of the anti-VEGF aptamer EYE001 with poly (lactic-co-glycolic) acid microspheres. Invest Ophthalmol Vis Sci 2003; 44: 290-9.